Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report) and ...

Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Rhythm Pharmaceuticals, Inc. BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...

Rhythm Pharmaceuticals, Inc. has announced a collaboration with the Raymond A. Wood Foundation to conduct research on the impact of fatigue in individuals diagnosed with craniopharyngioma ...

BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...